Fig. 5

Empagliflozin induces ERK1/2 phosphorylation post cardiac IR injury. Western blots (Left) and band densities (Right) of phosphorylated STAT3 and total STAT3 (A), phosphorylated STAT1 and total STAT1 (B), phosphorylated STAT5 and total STAT5 (C), ventricular phosphorylated p38 MAPK and total p38 MAPK (D), phosphorylated AKT and total AKT (E), phosphorylated GSK-3β and total GSK-3β (F), phosphorylated ERK1/2 and total ERK1/2 (G), isolated from rats in sham, control and empagliflozin group after 20 min of reperfusion (n = 5 per group). ***P < 0.001 vs. sham, ^###P < 0.001 vs. CON. Sham, sham-operated group; CON, control; Em, empagliflozin. (H) Left, phosphorylated ERK1/2 immunoreactivity in the cytoplasm of the myocytes of hearts, with and without empagliflozin. ***P < 0.001 vs. sham, ^###P < 0.001 vs. CON. Sham, sham-operated group. CON, control. Right, the bar graph illustrates the difference of phosphorylated ERK1/2 expression from each experimental group. Data are presented as mean ± SD. Each group, n = 5